Selonsertib is a drug that has been studied in the field of liver diseases, specifically non-alcoholic steatohepatitis (NASH). NASH is a type of fatty liver disease that can progress to cirrhosis and liver failure if left untreated. Selonsertib is a selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1), a protein that is involved in inflammation and cell death in the liver. By targeting ASK1, selonsertib aims to reduce inflammation and fibrosis in the liver, potentially slowing down the progression of NASH. Clinical trials have been conducted to evaluate the efficacy and safety of selonsertib in patients with NASH, with mixed results so far. More research is needed to determine the overall effectiveness of selonsertib in treating NASH.